131 related articles for article (PubMed ID: 28392461)
61. Optimization of the assembly efficiency for lidamycin chromophore bound to its apoprotein: a case study using orthogonal array.
Zhong GS; Guo XF; Zhang SH; Zhen YS
Biomed Environ Sci; 2011 Dec; 24(6):602-7. PubMed ID: 22365395
[TBL] [Abstract][Full Text] [Related]
62. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
63. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Venkatesha VA; Joshi A; Venkataraman M; Sonawane V; Bhatia D; Tannu P; Bose J; Choudhari S; Srivastava A; Pandey PK; Lad VJ; Sangana R; Ahmed T; Damre A; Deore V; Sahu B; Kumar S; Sharma S; Agarwal VR
Mol Cancer; 2014 Dec; 13():259. PubMed ID: 25466244
[TBL] [Abstract][Full Text] [Related]
64. PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells.
Zhao XM; Pan SY; Huang QL; Lu YN; Wu XH; Chang JH; Liu ZB; Cai XW; Liu Q; Wang JL; Fu XL
Oncotarget; 2016 Aug; 7(31):49384-49396. PubMed ID: 27283902
[TBL] [Abstract][Full Text] [Related]
65. An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K‑ras mutation.
Sheng W; Geng J; Li L; Shang Y; Jiang M; Zhen Y
Oncol Rep; 2020 Mar; 43(3):851-863. PubMed ID: 32020213
[TBL] [Abstract][Full Text] [Related]
66. The Recombinant and Reconstituted Novel Albumin-Lidamycin Conjugate Shows Lasting Tumor Imaging and Intensively Enhanced Therapeutic Efficacy.
Li L; Hu L; Zhao CY; Zhang SH; Wang R; Li Y; Shao RG; Zhen YS
Bioconjug Chem; 2018 Sep; 29(9):3104-3112. PubMed ID: 30105903
[TBL] [Abstract][Full Text] [Related]
67. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
[TBL] [Abstract][Full Text] [Related]
68. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
[TBL] [Abstract][Full Text] [Related]
69. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
[TBL] [Abstract][Full Text] [Related]
70. A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers.
Zhou DD; Zhai XT; Zhang LW; Xie ZH; Wang Y; Zhen YS; Gao RJ; Miao QF
NPJ Precis Oncol; 2024 Apr; 8(1):94. PubMed ID: 38654141
[TBL] [Abstract][Full Text] [Related]
71. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
Hu P; Han DX; Ruan RS; Zheng LM; Chou SH; Tzeng CM
Oncotarget; 2016 Jun; 7(24):35741-35752. PubMed ID: 26848869
[TBL] [Abstract][Full Text] [Related]
72. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
[TBL] [Abstract][Full Text] [Related]
73. MMP-2 and MMP-13 affect vasculogenic mimicry formation in large cell lung cancer.
Li Y; Sun B; Zhao X; Wang X; Zhang D; Gu Q; Liu T
J Cell Mol Med; 2017 Dec; 21(12):3741-3751. PubMed ID: 28766880
[TBL] [Abstract][Full Text] [Related]
74. Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer.
Zhang Q; Liu X; Xu S; Li C; Zhang Y; Yang J; Zheng J
Cancer Biother Radiopharm; 2012 Aug; 27(6):384-91. PubMed ID: 22651685
[TBL] [Abstract][Full Text] [Related]
75. An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma.
Wei M; Liu X; Cao C; Yang J; Lv Y; Huang J; Wang Y; Qin Y
BMB Rep; 2018 Nov; 51(11):572-577. PubMed ID: 30021673
[TBL] [Abstract][Full Text] [Related]
76. TGF alpha-PE40 inhibits non-small cell lung cancer growth.
Draoui M; Siegall CB; FitzGerald D; Pastan I; Moody TW
Life Sci; 1994; 54(7):445-53. PubMed ID: 8309347
[TBL] [Abstract][Full Text] [Related]
77. Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer.
Wang YY; Li L; Liu XJ; Miao QF; Li Y; Zhang MR; Zhen YS
J Pharm Anal; 2022 Apr; 12(2):232-242. PubMed ID: 35582405
[TBL] [Abstract][Full Text] [Related]
78. Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
Int J Pharm; 2018 Aug; 547(1-2):611-620. PubMed ID: 29933059
[TBL] [Abstract][Full Text] [Related]
79. Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis.
Long JT; Cheang TY; Zhuo SY; Zeng RF; Dai QS; Li HP; Fang S
J Nanobiotechnology; 2014 Sep; 12():37. PubMed ID: 25266303
[TBL] [Abstract][Full Text] [Related]
80. Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.
Arkadash V; Yosef G; Shirian J; Cohen I; Horev Y; Grossman M; Sagi I; Radisky ES; Shifman JM; Papo N
J Biol Chem; 2017 Feb; 292(8):3481-3495. PubMed ID: 28087697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
